47 results about "Ginsenoside CK" patented technology

The invention discloses an anti-tumor medicine composition combined with a PARG inhibitor and application. Through natural product library screening and CCK-8 experiments, it is found that PARG knockout gastric cancer cells show significantly enhanced sensitivity to ginsenoside CK. Further clone formation experimental analysis shows that PARG knockout significantly enhances the inhibitory effect of ginsenoside CK on gastric cancer cell proliferation. In in-vivo experiments, a CDX model is utilized to verify that PARG knockout can significantly enhance the anti-tumor activity of ginsenoside CK on gastric cancer. The discovery provides an important experimental basis for clinical application of PARG as a gastric cancer treatment target and ginsenoside CK as a potential treatment drug. The research finds that the PARG inhibitor and ginsenoside CK are combined to achieve a better killing effect on other various cancer cells, and it is indicated that improvement of the effect is broad-spectrum.

The invention belongs to the technical field of biology, and particularly relates to a construction method and application of a tobacco plant for expressing rare ginsenoside. According to the method, dammarendiol synthase DDS, cytochrome P450 CYP716A47 and glycosyl transferase UGTPg1 / UGTPg45 are added into tobacco, heterologous synthesis of rare ginsenosides CK and Rh2 is achieved, dependence on traditional ginseng cultivation extraction is avoided, and cost is remarkably reduced and efficiency is remarkably improved. The characteristics of short growth cycle and easy culture of tobacco are utilized to overcome the problems of low efficiency and low yield of traditional synthesis; positive transgenic tobacco leaves are dedifferentiated to form callus cells, so that materials are provided for large-scale fermentation, and an industrial production foundation is laid.

The invention relates to the technical field of gene engineering and enzyme engineering, in particular to a beta-glucosidase mutant with high catalytic activity and application of the beta-glucosidase mutant. The sequence of the beta-glucosidase mutant is obtained by carrying out any one of the following mutations on an amino acid sequence as shown in SEQ ID No.1: respectively mutating proline at the 95th site and arginine at the 178th site into cysteine; phenylalanine at the 98th site and arginine at the 178th site are respectively mutated into cysteine. The obtained mutants P95C / R178C and F98C / R178C have high enzyme activity, ginsenoside Rb1 can be converted into CK, the conversion efficiency is respectively improved by 83.52% and 105.79% compared with that of wild beta-glucosidase, and the industrial application of enzymatic conversion of rare ginsenoside CK is promoted.

The invention relates to a ginsenoside nano-micelle based on intermolecular self-assembly as well as a preparation method and application thereof, and belongs to the technical field of nano-micelles. The preparation process of the ginsenoside nano-micelle comprises the following steps: converting raw materials of panaxadiol saponin by using a compound enzyme, removing impurities by passing through a column, carrying out intermolecular self-assembly under ultrasonic, and purifying; the ginsenoside nano-micelle is prepared from ginsenoside Rg5, ginsenoside CK and ginsenoside Rg3, and the ginsenoside Rg5, the ginsenoside CK and the ginsenoside Rg3 are used as auxiliary materials. The ginsenoside nano-micelle is prepared in an intermolecular self-assembly mode, the water solubility and stability of ginsenoside are remarkably improved, the ginsenoside can be uniformly dispersed in a water solution and is not prone to precipitation and degradation, meanwhile, the skin permeability of the ginsenoside can be effectively improved through the nanoscale micelle structure, and the skin permeability of the ginsenoside can be effectively improved. Therefore, the skin care effect of the ginsenoside is fully exerted, and the ginsenoside is very suitable for being applied to skin care products.

The invention belongs to the technical field of saponin synthesis, and particularly relates to a method for synthesizing ginsenoside in tomatoes. The invention aims to provide a new choice for synthesizing ginsenoside. According to the technical scheme, the method for synthesizing the ginsenoside in the tomato is realized by increasing the expression quantity of genes PnSE, PnDS, CYP716A47 and GT95 in the tomato. According to the invention, the PnSE / PnDS / CYP450A47 / GT95 gene of panax notoginseng is co-overexpressed in the plant chassis tomato for the first time, heterologous synthesis of ginsenoside CK in plants is realized, and a new way is provided for extraction of ginsenoside CK.

The present patent application discloses an antidepressant composition containing rare ginsenosides and a preparation method thereof. The antidepressant composition of the present application contains ginseng hydrolysate, Zizyphus jujuba powder and gamma-aminobutyric acid and other functional ingredients, wherein the ginseng hydrolysate is rich in rare ginsenoside CK. The antidepressant composition of the present application has good antidepressant efficacy, can significantly increase the content of 5-hydroxytryptophan (5-HT) and gamma-aminobutyric acid (GABA) in brain tissue, achieve better enhancement of emotional stability and cognitive flexibility, improve anhedonia, relieve anxiety comorbidity and sleep disorders, provide a steady-state foundation for emotional recovery, and improve the efficacy of antidepressants. At the same time, the antidepressant composition of the present application has no side effects on the human body, the product has high safety, the preparation method is simple, the quality is controllable, and the industrialized continuous production can be realized.

The invention relates to an anti-wrinkle composition, application thereof and cosmetics, the anti-wrinkle composition comprises ginsenoside CK and low-molecular-weight sodium hyaluronate, the mass ratio of the ginsenoside CK to the low-molecular-weight sodium hyaluronate is 1: (5-100), and the molecular weight of the low-molecular-weight sodium hyaluronate does not exceed 5000 Daltons. The anti-wrinkle composition has the beneficial effects that the usage amount of Ectoine and rare ginsenoside CK can be reduced, so that the cost is saved, and meanwhile, an excellent anti-wrinkle effect is realized.

The invention discloses carboxymethyl chitosan nano freeze-dried powder as well as a preparation method and application thereof, and belongs to the technical field of nano medicines. The preparation method of the carboxymethyl chitosan nano freeze-dried powder comprises the following steps: dissolving a carboxymethyl chitosan deoxycholic acid polymer with an alcohol solvent, adding the dissolved carboxymethyl chitosan deoxycholic acid polymer into water to prepare a turbid liquid, and carrying out first dialysis to obtain a carboxymethyl chitosan deoxycholic acid nano particle solution; adding ginsenoside CK powder into the solution, stirring at room temperature to enable ginsenoside CK to be loaded on the nanoparticles, and performing second dialysis with water after stirring to obtain a ginsenoside CK carboxymethyl chitosan-deoxycholic acid nanoparticle suspension; and then freeze-drying to obtain the carboxymethyl chitosan nano freeze-dried powder. The prepared carboxymethyl chitosan nano freeze-dried powder has controllable particle size and high drug loading capacity, can specifically release drugs in a tumor slightly acidic environment, remarkably improves the liver cancer treatment effect and biological safety, and has great market application potential.

The invention provides an application of Ginsenoside C-K in preparation of a medicine for resisting gram bacterial infection, and the CAS number of the Ginsenoside C-K is 39262-14-1, the CAS number of the Ginsenoside C-K is 39262-14-1, and the CAS number of the Ginsenoside C-K is 39262-14-1. The Ginsenoside C-K is used for preparing a medicine for resisting gram-positive bacterium infection, and the Ginsenoside C-K and a polypeptide antibiotic polymyxin B are combined to be used for preparing a medicine for resisting gram-negative bacterium infection. According to the technical scheme, the novel medical application of the Ginsenoside C-K. The Ginsenoside C-K has the effects of inhibiting growth of gram-positive bacteria and formation of a biofilm, and the Ginsenoside C-K and polypeptide antibiotic polymyxin B are combined to have the effect of reversing drug resistance of gram-negative bacteria to the polymyxin B. The invention further discloses a preparation method of the Ginsenoside C-K.

The invention relates to the technical field of gene engineering. The invention provides a glucosidase truncated mutant with improved thermal activity and pH adaptability. The amino acid sequence of the mutant is as shown in SEQ ID NO. 1. On the basis of a homologous modeling method, specific amino acid is truncated to optimize a glucosidase structure, the thermal activity and pH adaptability are improved, the optimum temperature is increased by 10 DEG C, and gt is reserved under the condition that the pH is 5.0; the activity is 50%, and the affinity of a substrate is improved (Km is equal to 0.8517 mM). The invention further provides application of the mutant in preparation of rare ginsenoside CK. The high-titer yield of the rare ginsenoside CK prepared from the mutant is remarkably increased compared with that of the rare ginsenoside CK prepared from a wild enzyme. The preparation process is simple and has the potential of being applied to large-scale industrial production.

The present application relates to the technical field of nanomedicine, in particular to a β-cyclodextrin-carboxymethyl chitosan-deoxycholic acid nanoparticle carrying ginsenoside CK, a preparation method and application. A first esterification reaction is performed between a β-cyclodextrin solution and a carboxyl-activated carboxymethyl chitosan solution to obtain a β-cyclodextrin-carboxymethyl chitosan polymer; a second esterification or amidation reaction is performed by adding carboxyl-activated deoxycholic acid to the β-cyclodextrin-carboxymethyl chitosan polymer to obtain a β-cyclodextrin-carboxymethyl chitosan-deoxycholic acid polymer; an ethanol solution of ginsenoside CK is mixed with a water solution of the β-cyclodextrin-carboxymethyl chitosan-deoxycholic acid polymer to obtain a whole particle, and a freeze-drying protective agent is added for freeze-drying to obtain the β-cyclodextrin-carboxymethyl chitosan-deoxycholic acid nanoparticle carrying ginsenoside CK. The present application focuses on the design of an intelligent carrier, realizes the synergistic optimization of high drug loading and intelligent delivery, and overcomes the defects of the prior art.

This invention discloses a β-glucosidase, its preparation method, and its applications, relating to the field of genetic engineering technology. The amino acid sequence of the β-glucosidase is shown in SEQ ID NO:1. The nucleotide sequence encoding this enzyme, optimized for codon bias in *E. coli*, is shown in SEQ ID NO:2. The constructed recombinant expression vector contains an IPTG inducible promoter, a ribosome binding site, a 6×His tag, a TEV protease recognition site, a flexible linker peptide, and the sequence shown in SEQ ID NO:2. The recombinant expression vector is transformed into *E. coli*, and after induction expression, high-density fermentation, and affinity purification, a highly soluble and active target enzyme is obtained. This enzyme can efficiently catalyze the conversion of ginsenoside Rb1 to rare ginsenoside CK, with a conversion rate exceeding 82%. This invention improves the soluble expression level and preparation efficiency of the target enzyme, making it suitable for industrial production.

The invention relates to the technical field of fermentation engineering, and particularly discloses a preparation method and application of a ginseng leavening for improving the content of transformed ginsenoside CK. The preparation method comprises the following fermentation conditions: 1) performing carbon source and nitrogen source combined regulation on ginseng root hair fermentation liquor; (2) inoculating the three probiotics into the ginseng root hair fermentation liquor in stages, and carrying out synergistic fermentation; 3) regulating and controlling the dissolved oxygen level in stages; 4) regulating and controlling fermentation conditions by stages; the carbon source comprises fructo-oligosaccharide, inulin and xylooligosaccharide; the nitrogen source comprises soybean protein isolate and pea protein; the probiotics comprise strains of the genus Lactobacillus, the genus Bifidobacterium and the genus Saccharomyces. According to the method, the yield of ginsenoside CK in the ginseng leavening can be remarkably increased, the fermentation efficiency is improved, and the fermentation period is shortened.

The present application relates to the technical field of bioengineering, and particularly relates to a beta-glucosidase freeze-drying protective agent and application thereof in production of CK. The present application utilizes beta-glucosidase Bgp3 to prepare rare ginsenoside CK, adopts a freeze-drying technology to prepare a freeze-dried powder from Bgp3 protein supernatant, and adds a specific freeze-drying protective agent before freeze-drying, so as to protect the enzyme activity, improve the enzyme stability, and facilitate storage and longer preservation time. The present application adds a freeze-drying protective agent with a combination of trehalose, arginine and mannitol as raw materials, and the Bgp3 freeze-dried powder prepared without the protective agent has high catalytic efficiency. The present application provides a method for producing rare ginsenoside CK by utilizing beta-glucosidase Bgp3, which has high bioconversion rate, mild reaction conditions, simple equipment and easy operation, and provides technical support for industrial production of rare ginsenoside CK.

Compositions with weight-loss effects and their applications belong to the field of biomedicine. To improve the fat-reducing effect and further solve the off-target effect problem caused by existing weight-loss mechanisms, the composition includes fucoxanthin 0.8%~2.5%, ginsenoside CK 0.6%~1.2%, black ginseng active peptide 0.3%~0.6%, amylase inhibitor 12%~30%, prickly pear cactus extract 6%~15%, allicin 0.2%~0.6%, and excipients. This invention achieves weight regulation through comprehensive synergy of multiple targets.

The invention provides a bacillus safensis Sys-Gs-001 strain for producing ginsenoside CK, the strain is preserved in the China Center for Type Culture Collection on November 24, 2025, the preservation number is CCTCC NO: M20252681, the preservation number is CCTCC NO: M20252681, the preservation number is CCTCC NO: M20252681, and the preservation number is CCTCC NO: M20252681. The 16S rDNA (ribosomal deoxyribonucleic acid) sequence of the strain is as shown in SEQ ID NO. 1. The bacillus safensis Sys-Gs-001 strain provided by the invention can produce ginsenoside CK through metabolism, can be subjected to large-scale fermentation culture in a short time, is relatively low in fermentation cost, is not limited by conditions such as time domains and seasons, and has remarkable advantages. Meanwhile, the invention also provides optimized microbial fermentation conditions and a formula of the culture medium, and the yield of the ginsenoside CK is relatively high.

The invention relates to the technical field of supramolecules, in particular to a ginsenoside CK-aescin supramolecule, in the supramolecule, ginsenoside CK and aescin are formed through a non-covalent bond, the mass ratio of ginsenoside CK to aescin is 1: (1-25), and a preparation method comprises the following steps: dispersing aescin in an organic solvent aqueous solution to prepare a suspension A, dissolving ginsenoside CK in ethanol to prepare a solution D for later use; stirring the suspension A to obtain a suspension B; performing ultrasonic treatment on the suspension B to obtain emulsion C; slowly adding the emulsion C into the solution D while stirring, stirring to obtain a ginsenoside CK-aescin supramolecular solution crude product, and dialyzing. According to the ginsenoside CK-aescin supramolecule prepared by the invention, an IVPT test shows that the transdermal absorption capacity of the ginsenoside CK-aescin supramolecule is remarkably improved, so that the ginsenoside CK-aescin supramolecule can be better absorbed by human skin, and the efficacy of the ginsenoside CK-aescin supramolecule is favorably exerted.

This patent application discloses a rare ginsenoside functional composition and its preparation method. The rare ginsenoside functional composition of this invention comprises active ingredients such as ginseng enzymatic hydrolysate and ginseng fermentation product, wherein the ginseng enzymatic hydrolysate is rich in rare ginsenoside CK, and the ginseng fermentation product is rich in ginsenosides Rk1, Rg5, Rk3, and Rh4. The rare ginsenoside functional composition of this invention has good effects in relieving mental stress and antidepressant effects.

The invention relates to the technical field of cosmetics, in particular to a ginsenoside CK nanoscale bilayer inclusion as well as a preparation method and application thereof. According to the invention, the stability problem of rare ginsenoside CK applied to cosmetics is solved through a nano-scale bilayer wrapping technology, and the stability and bioavailability of ginsenoside CK are improved. The preparation method of the inclusion provided by the invention is simple, can realize mass production, and is safe and stable, and the prepared ginsenoside CK nano-scale bilayer inclusion can be suitable for various dosage forms of cosmetics.

The present application belongs to the field of biological medicine, and relates to application of ginsenoside CK in preparation of a porcine oocyte damage inhibitor. The present application aims to explore the influence of CK on in-vitro maturation of porcine oocytes induced by BaP and the embryo development capacity thereof. The research of the present application finds that adding CK can improve in-vitro maturation of porcine oocytes and subsequent embryo development after damage induced by BaP by increasing the antioxidant activity of oocytes and improving the function of mitochondria.

The invention provides a hair disulfide bond repairing composition and application thereof, and relates to the technical field of cosmetics, the hair disulfide bond repairing composition comprises ginsenoside CK, a recombinant collagen composition and multiple hydrolyzed protein, the recombinant collagen composition comprises small-molecule recombinant collagen, middle-molecule recombinant collagen and large-molecule recombinant collagen, and the multiple hydrolyzed protein comprises hydrolyzed vegetable protein, hydrolyzed sericin, hydrolyzed wheat protein, hydrolyzed soybean protein and hydrolyzed corn protein. The ginsenoside CK, the recombinant collagen composition and the multi-hydrolyzed protein are combined for use, so that the antioxidant capacity of the composition reaches the highest level, active oxygen can be removed to the greatest extent to prevent new fracture of disulfide bonds, the capacity of repairing the disulfide bonds can reach the highest, and the effect of repairing the disulfide bonds is achieved. The problem that hair is easy to break due to factors such as dyeing, perming and high temperature is fundamentally solved.

The invention relates to the technical field of cosmetics, in particular to a rare ginsenoside CK / Rg3 composite nano solution and a preparation method and application thereof. The composite nano solution of the rare ginsenoside comprises micelles and a solvent, the micelle comprises a first carrier, a second carrier and an active component wrapped by the first carrier and the second carrier; the first carrier comprises tocophen; the second carrier comprises at least one of chitosan and a derivative of the chitosan; the active ingredients comprise ginsenoside CK and ginsenoside Rg3 in a mass ratio of (1: 5)-(5: 1); the solvent comprises a solubilizer and water. The rare ginsenoside composite nano solution provided by the invention has the advantages of good stability and high transdermal absorption efficiency.

The invention discloses a beta-glucosidase BglSK mutant and an application of the beta-glucosidase BglSK mutant. The BglSK mutant is mutated by taking an amino acid sequence as shown in SEQ ID NO. 1 as a benchmark. According to the beta-glucosidase BglSK mutant disclosed by the invention, one or more amino acid residues are introduced at a specific site for substitution, so that the thermal stability and / or catalytic activity of beta-glucosidase are / is remarkably improved; in addition, ginsenoside Rd or analogues thereof can be efficiently catalyzed, and rare ginsenoside F2 and / or rare ginsenoside CK can be directionally generated. According to the beta-glucosidase BglSK mutant disclosed by the invention, large-scale production of rare ginsenoside is successfully realized, and the beta-glucosidase BglSK mutant has huge industrial application prospect and value.

The invention relates to application of ginsenoside CK in preparation of drugs for treating diseases by activating PPAR gamma and / or CPT1A pathways, and belongs to the technical field of medicines.The action mechanism of ginsenoside CK in prevention or treatment of metabolism-related fatty liver diseases (MAFLD) is obtained for the first time through research, and by establishing an MAFLD mouse model and an MAFLD cell model respectively, the action mechanism of ginsenoside CK in prevention or treatment of metabolism-related fatty liver diseases is obtained. Through PPAR gamma and CPT1A inhibition and ginsenoside CK intervention tests, the application of ginsenoside CK in remarkably reducing expression of ACC1 / FAS / SREBP1c, improving expression of CPT1 / CPT2, reducing serum TG / TC / FFA / LDL-C / ALT / AST level, increasing HDL-C, reducing hypoglycemia / insulin level and insulin resistance index, reducing ROS accumulation of hepatocytes, improving mitochondrial membrane potential, improving mitochondrial membrane potential, reducing liver cancer, reducing liver cancer, reducing liver cancer, reducing liver cancer, reducing liver cancer, reducing liver cancer and reducing liver cancer. The invention relates to a mechanism for preventing or treating MAFLD by inhibiting an NF-kappa B / JNK inflammation pathway and the like, and provides a new candidate component for research and development of MAFLD treatment drugs.

The invention relates to the technical field of nano-drugs, in particular to beta-cyclodextrin-carboxymethyl chitosan-deoxycholic acid nanoparticles loaded with ginsenoside CK as well as a preparation method and application of the beta-cyclodextrin-carboxymethyl chitosan-deoxycholic acid nanoparticles loaded with ginsenoside CK. The method comprises the following steps: carrying out first esterification reaction on a beta-cyclodextrin solution and a carboxyl-activated carboxymethyl chitosan solution to obtain a beta-cyclodextrin-carboxymethyl chitosan polymer; dropwise adding carboxyl activated deoxycholic acid into the beta-cyclodextrin-carboxymethyl chitosan polymer, and carrying out second esterification or amidation reaction, so as to obtain a beta-cyclodextrin-carboxymethyl chitosan-deoxycholic acid polymer; the preparation method comprises the following steps: mixing an ethanol solution of ginsenoside CK with a beta-cyclodextrin-carboxymethyl chitosan-deoxycholic acid polymer aqueous solution, carrying out size stabilization, adding a freeze-drying protective additive, and carrying out freeze drying so as to obtain the ginsenoside CK-loaded beta-cyclodextrin-carboxymethyl chitosan-deoxycholic acid nanoparticles. The invention focuses on intelligent carrier design, realizes collaborative optimization of high drug loading capacity and intelligent delivery, and overcomes the defects in the prior art.

The invention discloses a chemical composition for regulating scalp ecology and a preparation method and application, the chemical composition comprises a barrier repairing component, an oil control regulating component and an anti-dandruff micro-ecological component, and the barrier repairing component comprises an agilawood extract and an African amomum kravanh seed extract; the oil-control adjusting component comprises an orchid / leaf / stem extract, ginsenoside CK and a red clover extract; the anti-dandruff micro-ecological component comprises a crocus sativus extract, hydrolyzed silk, saccharomycetes / rice fermentation product filtrate, saccharomycetes / barley seed fermentation product filtrate and a lactic acid bacteria fermentation product. According to the composition disclosed by the invention, a key signal channel is activated and an inflammatory factor repair barrier is regulated through PPARalpha; the sebum metabolism is regulated from multiple pathways of hormone signal, lipid synthesis, cell differentiation and inflammatory environment AMPK-PPARgamma-AR-ACC-COX2 (AMPK-PPARgamma-AR-ACC-COX2); the healthy scalp micro-ecology is reconstructed through the strategy of'bacteriostasis-bacteria cultivation-physical protection '.

The invention relates to the technical field of bioengineering, in particular to recombinant glucoside hydrolase and application thereof in preparation of rare ginsenoside CK. Compared with glucoside hydrolase with an amino acid sequence shown as SEQ ID NO: 1, the recombinant glucoside hydrolase has R234K; and having one or more of R233K and W288Y, as well as one or more of R233K and W288Y. The recombinant glucoside hydrolase can be used for efficiently and specifically preparing rare ginsenoside CK, and is high in conversion rate and suitable for industrial production.

The invention provides an anti-tumor composition as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The anti-tumor composition disclosed by the invention is prepared from the following raw materials in parts by mass: 18 to 22 parts of ginsenoside Rg3, 3 to 7 parts of ginsenoside CK, 28 to 32 parts of ganoderma lucidum polysaccharide, 23 to 27 parts of astragalus polysaccharide, 8 to 12 parts of lentinan, 16 to 20 parts of panax notoginseng saponins, 9 to 11 parts of resveratrol, 13 to 17 parts of curcumin, 6 to 10 parts of dihydromyricetin and 7 to 9 parts of sophocarpidine. The ratio of the total mass of the ganoderan and the astragalus polysaccharide to the total mass of the ginsenoside Rg3 and the panax notoginseng saponins is (1.3-1.6): 1. Through a multi-target and multi-path synergistic effect mechanism, tumor cell proliferation can be directly inhibited, apoptosis can be induced, the cell cycle can be retarded, tumor angiogenesis can be inhibited, the immune function of the body can be enhanced, the antioxidant effect can be exerted, tumor invasion and metastasis can be inhibited, meanwhile, the obvious synergistic and toxicity reducing effects can be shown in combined chemotherapy application, and the application prospect is wide. And a new technical scheme is provided for comprehensive treatment of tumors.

The application relates to the field of biotechnology, and particularly discloses a mutant strain Cbg61-T37, a co-expression strain Cbg61-T37-MPR1 and a construction method and application thereof. The mutant strain Cbg61-T37 is preserved in the China General Microbiological Culture Collection Center on August 18, 2025, has a preservation number of CGMCC No. 35649, and is classified and named as Pichia pastoris. Pichia pastoris The mutant strain Cbg61-T37 provided by the application has an enzyme hydrolysis activity of 62.9 U / mg, which is increased by 43.8% compared to the original strain. Therefore, the mutant strain Cbg61-T37 is more conducive to catalysis and synthesis of the rare ginsenoside CK.

The application discloses a beta-glucosidase BglSK mutant and application thereof. The BglSK mutant is mutated based on the amino acid sequence shown in SEQ ID NO. 1. The beta-glucosidase BglSK mutant of the application significantly improves the thermal stability and / or catalytic activity of the beta-glucosidase by introducing one or more amino acid residue substitutions at specific sites. In addition, the beta-glucosidase BglSK mutant can efficiently catalyze ginsenoside Rd or an analogue thereof to direct generation of rare ginsenoside F2 and / or rare ginsenoside CK. The beta-glucosidase BglSK mutant of the application successfully realizes large-scale production of rare ginsenosides, and has great industrial application prospect and value.